The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
One task, one interaction, one pair, experts advocate
The endorsement follows overwhelming support for the share swap preceding the merger,
The conflict is also triggering a widening public health emergency
The protections extend through at least 2035, with the potential for further extensions
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Subscribe To Our Newsletter & Stay Updated
